Compare Piramal Healthcare with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs TORRENT PHARMA - Comparison Results

PIRAMAL ENTERPRISES     Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES TORRENT PHARMA PIRAMAL ENTERPRISES/
TORRENT PHARMA
 
P/E (TTM) x 18.2 58.4 31.2% View Chart
P/BV x 1.2 6.2 18.7% View Chart
Dividend Yield % 1.5 0.8 184.7%  

Financials

 PIRAMAL ENTERPRISES   TORRENT PHARMA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-19
TORRENT PHARMA
Mar-18
PIRAMAL ENTERPRISES/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs3,3031,550 213.1%   
Low Rs1,7971,144 157.1%   
Sales per share (Unadj.) Rs716.5354.7 202.0%  
Earnings per share (Unadj.) Rs79.740.1 198.9%  
Cash flow per share (Unadj.) Rs107.964.2 168.0%  
Dividends per share (Unadj.) Rs28.0014.00 200.0%  
Dividend yield (eoy) %1.11.0 105.6%  
Book value per share (Unadj.) Rs1,477.5273.1 540.9%  
Shares outstanding (eoy) m184.45169.22 109.0%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x3.63.8 93.7%   
Avg P/E ratio x32.033.6 95.2%  
P/CF ratio (eoy) x23.621.0 112.7%  
Price / Book Value ratio x1.74.9 35.0%  
Dividend payout %35.134.9 100.6%   
Avg Mkt Cap Rs m470,292227,897 206.4%   
No. of employees `0007.814.7 53.2%   
Total wages/salary Rs m22,50411,353 198.2%   
Avg. sales/employee Rs Th16,899.44,083.0 413.9%   
Avg. wages/employee Rs Th2,877.7772.3 372.6%   
Avg. net profit/employee Rs Th1,879.9461.3 407.5%   
INCOME DATA
Net Sales Rs m132,15360,021 220.2%  
Other income Rs m3,1282,988 104.7%   
Total revenues Rs m135,28163,009 214.7%   
Gross profit Rs m66,29013,493 491.3%  
Depreciation Rs m5,2024,086 127.3%   
Interest Rs m44,0973,085 1,429.5%   
Profit before tax Rs m20,1199,310 216.1%   
Minority Interest Rs m3,1940-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,6112,529 340.5%   
Profit after tax Rs m14,7016,781 216.8%  
Gross profit margin %50.222.5 223.1%  
Effective tax rate %42.827.2 157.6%   
Net profit margin %11.111.3 98.5%  
BALANCE SHEET DATA
Current assets Rs m122,74252,623 233.2%   
Current liabilities Rs m310,81052,022 597.5%   
Net working cap to sales %-142.31.0 -14,200.4%  
Current ratio x0.41.0 39.0%  
Inventory Days Days23120 19.3%  
Debtors Days Days3976 51.0%  
Net fixed assets Rs m116,90485,016 137.5%   
Share capital Rs m369846 43.6%   
"Free" reserves Rs m272,16145,376 599.8%   
Net worth Rs m272,53046,222 589.6%   
Long term debt Rs m270,19641,115 657.2%   
Total assets Rs m856,261142,432 601.2%  
Interest coverage x1.54.0 36.2%   
Debt to equity ratio x1.00.9 111.5%  
Sales to assets ratio x0.20.4 36.6%   
Return on assets %6.96.9 99.1%  
Return on equity %5.414.7 36.8%  
Return on capital %12.414.2 87.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,20014,580 104.3%   
Fx outflow Rs m4,8893,600 135.8%   
Net fx Rs m10,31210,980 93.9%   
CASH FLOW
From Operations Rs m-115,9758,942 -1,297.0%  
From Investments Rs m-8,265-47,070 17.6%  
From Financial Activity Rs m107,52534,174 314.6%  
Net Cashflow Rs m-16,650-3,655 455.5%  

Share Holding

Indian Promoters % 52.9 71.5 74.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 7.0 57.0%  
FIIs % 26.6 12.6 211.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 8.8 187.5%  
Shareholders   93,274 26,511 351.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   PLETHICO PHARMA  STRIDES PHARMA SCIENCE  FDC LTD.  JUBILANT LIFE SCIENCES  BIOCON   

Compare PIRAMAL ENTERPRISES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 642 Points; Automobile and Realty Stocks Plunge(Closing)

Indian share markets fell sharply today amid fears of rising crude oil prices and weakness in the rupee rattled investor sentiment.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY19); Net Profit Down 91.4% (Quarterly Result Update)

Apr 30, 2019 | Updated on Apr 30, 2019

For the quarter ended March 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 3 bn (down 91.4% YoY). Sales on the other hand came in at Rs 37 bn (up 23.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Sep 17, 2019 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 8-QTR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS